Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Disclosed are methods for the preparation of Tecovirimat for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.
Core Innovation
The disclosed invention concerns multiple synthetic routes for producing Tecovirimat (ST-246), including a claimed method that uses compound 9 as an intermediate. The route also involves compound 4, maleic anhydride, and cycloheptatriene; [procedural detail omitted for safety]. The partial description further identifies compounds 6, 9, 10, and 13 as useful synthesis intermediates and mentions alternative routes through protected hydrazide intermediates and an iodinated intermediate.
The background section is not included in the supplied partial content, so the problem being solved is not explicitly described in patent. The available text reports synthesis routes and product yield outcomes, but it does not state a specific limitation of prior approaches or explain why the claimed route is selected. Accordingly, no further problem statement can be attributed to the patent from this excerpt.
Claims Coverage
The supplied relevant claims identify two independent claims: claim 1 covers a method for producing the specified benzamide, and claim 5 claims compound 9.
Production of Tecovirimat through compound 9
Claim 1 covers a method for producing N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-benzamide using compound 4, maleic anhydride, compound 9, and cycloheptatriene. [Procedural detail omitted for safety.]
Compound 9
Claim 5 identifies compound 9 as a claimed compound. Its formula is not included in the supplied claim text.
The independent claims cover a method for producing the specified benzamide through a route involving compound 9 and compound 9 itself as a claimed compound.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Producing Tecovirimat (ST-246), also identified in claim 1 by its specified benzamide name.
Interested in licensing this patent?